A personalized cancer vaccine raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial.
from Top Health News -- ScienceDaily https://ift.tt/32b8tHe
Post a Comment